CD8A and neoplasm: TAMs express inhibitory immune checkpoints (including PD-L1) and release anti-inflammatory molecules (such as IL-10) that diminish the anti-tumor functionality of cytotoxic CD8+ T cells, inhibit CD8+ T cell recruitment, and increase the number of Treg cells (11, 19).